Downstream Process Development for the Purification of Biosimilar Insulin from Escherichia coli @BioRadLaboratoriesCorp
Downstream Process Development for the Purification of Biosimilar Insulin from Escherichia coli  @BioRadLaboratoriesCorp
Uploaded April 2023 | Updated September 2026, 2 weeks ago
With the increasing global demand for insulin products, there is a need to develop a more efficient and economical process for the production of recombinant insulin therapeutics. In this webcast, we present an efficient downstream processing workflow for recombinant human insulin production using E. coli as the host system. Data are presented for sample preparation and purification of proinsulin and insulin. Size exclusion was identified as a very efficient method for proinsulin desalting prior to purification. A strong cation exchange resin, Nuvia S Resin, was used in the capture step of proinsulin. Elution in a sodium citrate buffer achieved both good recovery and purity. For the insulin purification step, a high-resolution strong cation resin, Nuvia HR-S Resin, was found to be highly effective in removing a significant amount of higher molecular weight cleavage product impurities, as compared to known reverse-phase chromatography steps. This new purification workflow provides an excellent chromatographic tool for the purification of recombinant human insulin from E. coli inclusion bodies.

Overview
- Insulin and proinsulin purification workflow
- Effects of pH and conductivity
- Resin characteristics and optimization


We Are Bio-Rad.

Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.

Connect with Bio-Rad Online:
Website: bio-rad.com
LinkedIn: linkedin.com/company/1613226
Facebook: facebook.com/biorad
Twitter: twitter.com/BioRadLifeSci
Instagram: @BioRadLabs
Snapchat: @BioRadLabs

©2023 Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.

Music used by permission granted by royalty-free license from Pond5.com
Downstream Process Development for the Purification of Biosimilar Insulin from Escherichia coliDid You Know that ddPCR Tech Can be Used to Characterize the Poly(A) Tail Content in mRNA Products?Did You Know Bio-Rads Oncology Portfolio Includes the ddPCR Microsatellite Instability (MSI) Kit?Exploring the Potential of Chromatography Resins in Therapeutic Treatment DeliveryHigh Performance with GMP Ready CHT Prepacked Process-Scale ColumnsImpact of the QX700™ S Droplet Digital™ PCR System in Infectious Disease with hVIVO CROOvercome the Challenges of PK Assay Development Using TrailBlazer AntibodiesBio Rad.io Podcast — The Rise of Digital TherapeuticsBio-Rads Backyard BBQSingle-Cell ATAC Data Analysis Using Omnition PipelineDid You Know that the QX ONE™ Droplet Digital™ PCR System is Optimized for Biopharma?2023 Positive Droplet Award Interview with Dr. Deendayal Patel, PhD
Bio-Rad Laboratories |

Downstream Process Development for the Purification of Biosimilar Insulin from Escherichia coli

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER